JP2018087229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018087229A5 JP2018087229A5 JP2018026459A JP2018026459A JP2018087229A5 JP 2018087229 A5 JP2018087229 A5 JP 2018087229A5 JP 2018026459 A JP2018026459 A JP 2018026459A JP 2018026459 A JP2018026459 A JP 2018026459A JP 2018087229 A5 JP2018087229 A5 JP 2018087229A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor inhibitor
- vegf
- eye drops
- vegf receptor
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 claims 25
- 108091008605 VEGF receptors Proteins 0.000 claims 15
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 14
- 229940012356 eye drops Drugs 0.000 claims 14
- 235000002639 sodium chloride Nutrition 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 7
- 108091006082 receptor inhibitors Proteins 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000001344 Macular Edema Diseases 0.000 claims 5
- 206010025415 Macular oedema Diseases 0.000 claims 5
- 201000010230 macular retinal edema Diseases 0.000 claims 5
- 239000002612 dispersion medium Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000034508 Haemangioma of retina Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 229940057995 liquid paraffin Drugs 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910021538 borax Inorganic materials 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- -1 liquid paraffin Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 229940037001 sodium edetate Drugs 0.000 claims 1
- 239000004328 sodium tetraborate Substances 0.000 claims 1
- 235000010339 sodium tetraborate Nutrition 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021136152A JP7162708B2 (ja) | 2016-09-13 | 2021-08-24 | 医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016178599 | 2016-09-13 | ||
| JP2016178599 | 2016-09-13 | ||
| JP2017548494A JP6328860B1 (ja) | 2016-09-13 | 2017-09-13 | 医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548494A Division JP6328860B1 (ja) | 2016-09-13 | 2017-09-13 | 医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136152A Division JP7162708B2 (ja) | 2016-09-13 | 2021-08-24 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018087229A JP2018087229A (ja) | 2018-06-07 |
| JP2018087229A5 true JP2018087229A5 (https=) | 2020-11-12 |
| JP6935973B2 JP6935973B2 (ja) | 2021-09-15 |
Family
ID=61619580
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548494A Active JP6328860B1 (ja) | 2016-09-13 | 2017-09-13 | 医薬組成物 |
| JP2018026459A Active JP6935973B2 (ja) | 2016-09-13 | 2018-02-16 | 医薬組成物 |
| JP2021136152A Active JP7162708B2 (ja) | 2016-09-13 | 2021-08-24 | 医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548494A Active JP6328860B1 (ja) | 2016-09-13 | 2017-09-13 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021136152A Active JP7162708B2 (ja) | 2016-09-13 | 2021-08-24 | 医薬組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10894043B2 (https=) |
| EP (2) | EP3513809B9 (https=) |
| JP (3) | JP6328860B1 (https=) |
| KR (1) | KR102340311B1 (https=) |
| CN (1) | CN109641056A (https=) |
| AU (1) | AU2017326791B2 (https=) |
| CY (1) | CY1125495T1 (https=) |
| DK (1) | DK3513809T3 (https=) |
| EA (1) | EA038692B1 (https=) |
| ES (1) | ES2912105T3 (https=) |
| HR (1) | HRP20220489T1 (https=) |
| HU (1) | HUE058271T2 (https=) |
| IL (1) | IL265260B (https=) |
| LT (1) | LT3513809T (https=) |
| MX (1) | MX382732B (https=) |
| MY (1) | MY197845A (https=) |
| PH (1) | PH12019500423A1 (https=) |
| PL (1) | PL3513809T3 (https=) |
| PT (1) | PT3513809T (https=) |
| RS (1) | RS63136B9 (https=) |
| SI (1) | SI3513809T1 (https=) |
| TW (1) | TWI752083B (https=) |
| WO (1) | WO2018052053A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190388407A1 (en) | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| US20200345637A1 (en) * | 2018-01-19 | 2020-11-05 | Aiviva Biopharma, Inc. | Suspension compositions of multi-target inhibitors |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN110404079B (zh) * | 2018-04-27 | 2023-01-24 | 北京睿创康泰医药研究院有限公司 | 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物 |
| CN110693886B (zh) * | 2018-07-09 | 2022-12-06 | 天津医科大学 | 防治脑海绵状血管畸形病变的药物 |
| CN112839652A (zh) * | 2018-08-15 | 2021-05-25 | 艾葳生物科技有限公司 | VEGF和TGFβ的多激酶抑制剂及其用途 |
| KR102888598B1 (ko) | 2018-11-26 | 2025-11-20 | 아이비바 바이오파마, 인크. | 약물 전달을 위한 약학적 생분해성 겔 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| CN110051859B (zh) * | 2019-06-06 | 2020-06-12 | 鲁南制药集团股份有限公司 | 一种阿昔替尼环糊精包合物 |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| JP7217364B2 (ja) * | 2019-11-29 | 2023-02-02 | 千寿製薬株式会社 | 医薬組成物 |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| US20220031629A1 (en) * | 2020-07-31 | 2022-02-03 | Altaire Pharmaceuticals, Inc. | Ophthalmic compositions for removing meibum or inhibiting meibum buildup |
| WO2022156371A1 (zh) * | 2021-01-22 | 2022-07-28 | 成都瑞沐生物医药科技有限公司 | 一种眼用制剂的载体或辅料及其制备方法和应用 |
| WO2024002147A1 (zh) * | 2022-06-29 | 2024-01-04 | 正大天晴药业集团股份有限公司 | 喹啉衍生物或其盐环糊精包合物 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| TW202438066A (zh) * | 2023-03-24 | 2024-10-01 | 大陸商濟川藥業集團有限公司 | 一種瑞普洛莎奈米膠束組合物及其製備方法和用途 |
| PE20260040A1 (es) | 2023-04-11 | 2026-01-09 | Ocular Therapeutix Inc | Implante ocular que contiene un inhibidor de la tirosina cinasa |
| WO2024245409A1 (zh) * | 2023-06-02 | 2024-12-05 | 成都苑东生物制药股份有限公司 | 一种vegfr抑制剂的水合物，其晶型及其制备方法 |
| WO2026003803A1 (en) * | 2024-06-28 | 2026-01-02 | Kyowa Kirin Co., Ltd. | Tivozanib for treating posterior segment eye diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| JP3602513B2 (ja) | 2001-04-27 | 2004-12-15 | 麒麟麦酒株式会社 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
| US20080220075A1 (en) | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| ATE374199T1 (de) | 2002-10-21 | 2007-10-15 | Kirin Brewery | N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form |
| JP2004217649A (ja) | 2002-12-27 | 2004-08-05 | Santen Pharmaceut Co Ltd | 滲出型加齢黄斑変性治療剤 |
| WO2004060373A1 (ja) * | 2002-12-27 | 2004-07-22 | Santen Pharmaceutical Co., Ltd. | 滲出型加齢黄斑変性治療剤 |
| GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| US20100323957A1 (en) | 2007-11-19 | 2010-12-23 | The Regents Of The University Of California The Office Of The President | Novel assay for inhibitors of egfr |
| CN102408418A (zh) | 2011-10-21 | 2012-04-11 | 武汉迈德森医药科技有限公司 | Tivozanib酸性盐及其制备方法和晶型 |
| WO2013126799A1 (en) * | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CN111700879A (zh) * | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| KR101935780B1 (ko) | 2012-06-01 | 2019-01-07 | 엘지디스플레이 주식회사 | 액정표시장치 제조라인 |
| US20130316601A1 (en) | 2012-05-24 | 2013-11-28 | Cablofil, Inc. | Bonding clip |
| WO2014127335A1 (en) * | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| WO2016039422A1 (ja) | 2014-09-11 | 2016-03-17 | 大日本住友製薬株式会社 | 点眼用懸濁製剤 |
| TWI700085B (zh) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
-
2017
- 2017-09-13 JP JP2017548494A patent/JP6328860B1/ja active Active
- 2017-09-13 MY MYPI2019001248A patent/MY197845A/en unknown
- 2017-09-13 EP EP17850954.3A patent/EP3513809B9/en active Active
- 2017-09-13 RS RS20220385A patent/RS63136B9/sr unknown
- 2017-09-13 US US16/332,033 patent/US10894043B2/en active Active
- 2017-09-13 TW TW106131500A patent/TWI752083B/zh active
- 2017-09-13 HR HRP20220489TT patent/HRP20220489T1/hr unknown
- 2017-09-13 DK DK17850954.3T patent/DK3513809T3/da active
- 2017-09-13 ES ES17850954T patent/ES2912105T3/es active Active
- 2017-09-13 HU HUE17850954A patent/HUE058271T2/hu unknown
- 2017-09-13 CN CN201780053073.9A patent/CN109641056A/zh active Pending
- 2017-09-13 WO PCT/JP2017/033161 patent/WO2018052053A1/ja not_active Ceased
- 2017-09-13 LT LTEPPCT/JP2017/033161T patent/LT3513809T/lt unknown
- 2017-09-13 AU AU2017326791A patent/AU2017326791B2/en active Active
- 2017-09-13 MX MX2019002861A patent/MX382732B/es unknown
- 2017-09-13 SI SI201731114T patent/SI3513809T1/sl unknown
- 2017-09-13 PT PT178509543T patent/PT3513809T/pt unknown
- 2017-09-13 EA EA201990706A patent/EA038692B1/ru unknown
- 2017-09-13 KR KR1020197008652A patent/KR102340311B1/ko active Active
- 2017-09-13 EP EP22150617.3A patent/EP4000634A1/en active Pending
- 2017-09-13 PL PL17850954T patent/PL3513809T3/pl unknown
-
2018
- 2018-02-16 JP JP2018026459A patent/JP6935973B2/ja active Active
-
2019
- 2019-02-27 PH PH12019500423A patent/PH12019500423A1/en unknown
- 2019-03-10 IL IL265260A patent/IL265260B/en unknown
-
2020
- 2020-11-30 US US17/106,671 patent/US11951103B2/en active Active
-
2021
- 2021-08-24 JP JP2021136152A patent/JP7162708B2/ja active Active
-
2022
- 2022-05-17 CY CY20221100336T patent/CY1125495T1/el unknown
-
2024
- 2024-03-07 US US18/598,208 patent/US20240207246A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018087229A5 (https=) | ||
| HRP20220489T1 (hr) | Medicinski pripravak koji sadrži tivozanib | |
| Lin et al. | Stimulus‐responsive hydrogel for ophthalmic drug delivery | |
| JP2020530470A5 (https=) | ||
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| EP2429507B1 (de) | Phosphatfreie pharmazeutische zusammensetzung zur glaukombehandlung | |
| RU2016133980A (ru) | Композиции и способы для лечения заболеваний глаз | |
| JP2010526780A5 (https=) | ||
| CN114786480B (zh) | 使用内皮素受体拮抗剂治疗眼部疾病 | |
| KR20160126983A (ko) | 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법 | |
| JP4309974B2 (ja) | 眼科用製剤 | |
| JP2014533275A5 (https=) | ||
| HRP20220138T1 (hr) | Peptidni pripravci i postupci uporabe | |
| JP2018514590A5 (https=) | ||
| CN115103842A (zh) | 用于治疗眼部疾病的组合物 | |
| JP2017527600A5 (https=) | ||
| JP2020525416A5 (https=) | ||
| US20240199752A1 (en) | Treatment of ophthalmic diseases | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| CN102085175B (zh) | 一种眼用凝胶剂及其制备方法 | |
| JP2024521968A5 (https=) | ||
| JP2019534269A5 (https=) | ||
| CN104721136A (zh) | 一种布佐林胺眼用纳米混悬剂及其制备方法 | |
| CA2761740A1 (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
| Barkmeier et al. | Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab |